Medicare delays BALANCE Part D rollout, extending GLP-1 Bridge access through 2027, balancing obesity treatment access for seniors with payer concerns over cost, utilization, and sustainability.

Medicare delays BALANCE Part D rollout, extending GLP-1 Bridge access through 2027, balancing obesity treatment access for seniors with payer concerns over cost, utilization, and sustainability.

GLP-1 receptor agonists are emerging as potential Alzheimer’s therapies, targeting metabolic dysfunction and inflammation, signaling a shift beyond amyloid-focused treatments despite mixed clinical trial results.

New Phase 3 data highlight efgartigimod’s targeted efficacy in ocular myasthenia gravis, signaling a shift toward precision therapies that reduce treatment burden and improve patient-centered outcomes.

Phase 3 ADAPT SERON data show efgartigimod improves function in seronegative generalized myasthenia gravis, with FDA priority review potentially expanding targeted treatment options for underserved patients.

Reconsidering carboplatin in neoadjuvant HER2-positive breast cancer may reduce toxicity and resource use while maintaining outcomes, emphasizing individualized treatment decisions, patient experience, and careful monitoring.

Sexual health after cancer is often neglected, requiring routine discussion, multidisciplinary care, and better access to support addressing intimacy, body image, fertility, and quality-of-life challenges.

Younger breast cancer survivors face unique medical and psychosocial challenges, driving need for targeted research, personalized care plans, and multidisciplinary support to improve long-term outcomes and quality of life.

Overweight BMI in head and neck cancer may be linked to better outcomes, prompting reconsideration of weight’s role in prognosis, treatment planning, and nutritional support strategies.

Oral corticosteroids remain central in myasthenia gravis, but clinicians are shifting toward individualized dosing, combination therapies, and safer long-term strategies to reduce treatment burden and complications.